Our findings demonstrate the potential of TLR agonist-siRNA conjugates for targeted gene silencing coupled with TLR stimulation and immune activation in the tumor microenvironment.
A r t i c l e s
The ability of siRNAs to control the expression of specific genes makes them an attractive new class of drugs with broad potential for the treatment of diverse human diseases. Several recent studies have shown the feasibility of in vivo siRNA delivery, demonstrating therapeutic efficacy in mouse models [1] [2] [3] [4] and nonhuman primates 5, 6 . Nevertheless, efficient targeting of siRNA to specific cell types that are important constituents of the tumor microenvironment and active players in promoting tumor progression remains challenging.
The immune system can serve as an extrinsic tumor suppressor [7] [8] [9] . However, the tumor microenvironment is characterized by a lack of tumor-specific CD8 + T cells and an excess of regulatory T cells and myeloid-derived suppressor cells that promote tumor immune evasion 10, 11 . Myeloid cells and other immune cells in the tumor microenvironment also produce growth factors and angiogenic/metastatic factors critical for tumor progression 12 . The orchestration of these processes in the tumor microenvironment appears to be highly dependent on the oncogenic transcription factor Stat3 (refs. [13] [14] [15] [16] [17] . In particular, we and others have recently demonstrated a role for Stat3 in mediating tumor immune evasion 10, 17, 18 . Activated Stat3 in myeloid cells inhibits expression of a large number of immunostimulatory molecules related to T-helper cell 1 (Th1)-type responses while promoting production of several key immunosuppressive factors 17, 19, 20 as well as angiogenic factors 12 . In addition, by mediating signaling of certain cytokines and growth factors, notably interleukin (IL)-6, Stat3 activation in myeloid cells activates Stat3 in tumor cells, enhancing tumor cell proliferation and survival [21] [22] [23] [24] . Because Stat3 also restrains TLR-mediated Th1 immune responses 10, 17, 25 , we reasoned that simultaneously silencing Stat3 by siRNA and activating TLRs by their agonists could effectively shift the tumor microenvironment from pro-oncogenic to antitumor. A recent study using polymermediated in vivo transfection of 5′-triphosphate-Bcl2 siRNA has demonstrated the benefits of simultaneously inducing antitumor immunity and silencing a pro-oncogenic gene 4 .
Here we explored a strategy of linking siRNAs to synthetic oligonucleotide agonists of endosomal TLRs to combine targeted delivery to immune cells with TLR-dependent activation of antitumor immune responses. The endosomal location of oligonucleotide-binding TLRs such as TLR3, TLR7, TLR8 and TLR9 (refs. [26] [27] [28] might be advantageous in facilitating the uptake of the siRNA component into the cytosol for efficient gene silencing. To validate this concept, we chose TLR9specific oligodeoxynucleotides containing an unmethylated CpG motif (CpG oligonucleotide), which are already in clinical trials for melanoma 29 . Additionally, CpG oligonucleotides are efficiently internalized by various antigen-presenting cells, such as dendritic cells (DCs), macrophages and B cells. Their binding to TLR9 can initiate a cascade of innate and adaptive immune responses [28] [29] [30] . Myeloid cells and B cells are critical components of the tumor microenvironment that actively promote oncogenesis 12, 17, 19, 21, 22 . By linking the singlestranded CpG oligonucleotide with double-stranded siRNA, we have created a single synthetic molecule capable of delivering siRNA to myeloid and B cells, of silencing an immune checkpoint and oncogenic gene and of activating TLRs, leading to therapeutic antitumor immune responses.
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RESULTS

Construction of the CpG-Stat3 siRNA conjugate molecule
The antisense strand of the siRNA (27 mer) was coupled to a TLR9 agonist, CpG1668 oligonucleotide 31,32 using a carbon chain linker and hybridized to the 25-mer sense strand of the siRNA as shown in Figure 1a . A 25/27mer siRNA was chosen over the conventional 21-mer duplex to allow uncoupling of the siRNA from the CpG sequence by the Dicer enzyme once inside the cell. The asymmetric 25/27mer siRNA was optimized for specific processing by Dicer and was more potent in target gene silencing 33, 34 . Adding either CpG1688 alone or CpG-Stat3 siRNA conjugate to cultured DC2.4 dendritic cells resulted in a similar increase in expression of costimulatory CD40 and CD80 molecules, suggesting that CpG-Stat3 siRNA conjugate retains its capacity to activate TLR9 (Fig. 1b) . In addition, the immunostimulatory properties of CpG-siRNA conjugates do not differ from the effect of CpG alone as measured by production of inflammatory cytokines in primary cells and NF-κB/AP1 activation in a stable macrophage cell line ( Supplementary Fig. 1 ). To assess whether linking siRNA with CpG moiety would still allow Dicer processing, we compared in vitro Dicer activity on CpG-Stat3 siRNA substrate versus 25/27mer Stat3 siRNA. Both the CpG-Stat3 siRNA and Stat3 siRNA were processed to 21mer siRNA by recombinant Dicer (Fig. 1c) . Finally, to determine whether the CpG-Stat3 siRNA retains gene silencing function, the chimeric molecule was transfected into cells using Lipofectamine. Linking CpG oligonucleotide to siRNA did not interfere with Stat3 gene silencing (55% and 49% at protein level, respectively, as measured by densitometry) (Fig. 1d) .
In vitro uptake and gene silencing effects of the CpG-siRNA
To determine the specificity and efficiency of CpG-siRNA uptake, we incubated freshly prepared mouse splenocytes with CpG-Stat3 siRNA or an unconjugated Stat3 siRNA, in the absence of transfection reagents. Both the CpG-Stat3 siRNA and unconjugated Stat3 siRNA were labeled with fluorescein isothiocyanate (FITC). Fluorescein labeling of DCs, macrophages, B cells, granulocytes and T cells was assessed by flow cytometry, which indicated that the chimeric CpG-Stat3 siRNA was efficiently taken up by both plasmacytoid (CD11c + B220 + ) and conventional (CD11c + B220 − ) splenic DCs, macrophages (F4/ 80 + Gr1 − ) and B cells (B220 + CD11c − ), but only minimally by splenic granulocytes (Gr1 + F4/80 − ) or T cells (CD3 + ) ( Fig. 2a, Supplementary  Fig. 2 and Supplementary Table 1 ). This uptake pattern reflects the known distribution of TLR9 expression in murine leukocyte subsets 26, 35 . Analysis of intracellular staining of TLR9 in fixed CD11c + DCs by flow cytometry confirmed TLR9 expression ( Fig. 2a , bottom right). Unconjugated Stat3 siRNA was not efficiently incorporated into DCs even after 24 h incubation, demonstrating that linkage to the TLR9 ligand facilitates siRNA uptake ( Fig. 2a, bottom left) .
We further evaluated CpG-Stat3 siRNA-FITC uptake by DC 2.4 mouse DCs. Flow cytometry and fluorescent microscopy indicated that CpG-Stat3 siRNA-FITC was internalized by DC 2.4 cells with kinetics similar to CpG-oligonucleotides alone ( Fig. 2b, Fig. 3 ) and to those reported previously 36 . By 60 min, >80% of the DC 2.4 cells were positive for uptake of the conjugate, which was confirmed by confocal microscopic analysis. The uptake of the CpG-Stat3 siRNA-FITC was dose dependent (Fig. 2b , bottom row).
Confocal microscopic analyses further showed that at 1 h after incubation, the CpG-Stat3 siRNA colocalized with TLR9 within perinuclear endocytic vesicles ( Fig. 2c , two top rows; and Supplementary Fig. 4 ). This colocalization diminished at 2 and 4 h after CpG-Stat3 siRNA treatment ( Fig. 2c , two top rows). Previous studies have demonstrated that binding of the Dicer nuclease to the siRNA oligonucleotide is required for further siRNA processing to shorter 21-mer fragments that mediate RNA-induced silencing complex-dependent mRNA degradation 37 . We observed transient colocalization of the CpG-Stat3 siRNA with Dicer within 2 h after adding the oligonucleotide to cultured DCs ( Fig. 2c , two bottom rows; and Supplementary Fig. 4) . The colocalization of CpG-Stat3 siRNA and Dicer became weaker by 4 h (Fig. 2c ) and undetectable after 24 h (data not shown).
Gene silencing effects of the CpG-Stat3 siRNA in DC2.4 cells were determined by quantitative real-time PCR analysis of the Stat3 mRNA ( Fig. 2d) . Maximum effect on Stat3 silencing was observed at a relatively high concentration of CpG-Stat3 siRNA (1 µM) in serum-containing cell culture medium. GpC-conjugated Stat3 siRNA, which binds but does not activate TLR9 (ref. 36 ), failed to silence Stat3, suggesting a possible requirement of TLR9 activation for the CpG-siRNA to be processed. Further experiments demonstrated that in TLR9 -/myeloid cells and DCs, cellular uptake of CpG-Stat3 siRNA All confocal imaging studies were performed at least three times with similar results and the images acquired were characteristic for the majority of analyzed cells (Supplementary Fig. 4 Figure 13c .
A r t i c l e s was normal (Supplementary Fig. 5 ), but the gene silencing effect of CpG-Stat3 siRNA was impaired ( Fig. 2e) . We also confirmed the gene silencing effects using electrophoretic mobility shift assays (EMSA) to detect Stat3 DNA-binding activity in DC2.4 cells, which was induced by IL-10 stimulation (Fig. 2f) . Note that, as indicated above, stimulation using CpG itself also resulted in Stat3 activation 25, 38 (Fig. 2f) , thereby complicating the EMSA analysis for detection of Stat3 silencing. Nonetheless, at higher concentrations, CpG-Stat3 siRNA diminished Stat3 DNA-binding activity relative to the conjugate scrambled RNA controls. To demonstrate the generality of this approach to gene silencing, we used TLR9-positive mouse A20 B-cell lymphoma cells to test CpG-siRNA internalization (Supplementary Fig. 6a ) and gene silencing. A chimeric conjugate linking the CpG1668 oligonucleotide with an siRNA specific for firefly luciferase efficiently reduced luciferase activity in A20-Luc cells (Supplementary Fig. 6b ).
The CpG-Stat3 siRNA conjugate in vivo
Biodistribution experiments in naive tumor-free mice confirmed that CpG-Stat3 siRNA is specifically internalized by resident macrophages in different tissues as well as DCs and B cells in lymph nodes (Supplementary Fig. 7) . We next assessed the uptake of the CpG-Stat3 siRNA by macrophages and DCs in tumor-bearing mice. C57BL/6 mice with B16 tumors were injected peritumorally with CpG-Stat3 siRNA-FITC at 0.78 nmol (20 µg)/injection. Immunofluorescent staining showed myeloid cells positive for CpG-Stat3 siRNA accumulated at the injection site ( Fig. 3a) . Flow cytometry also indicated the presence of CpG-Stat3 siRNA in tumor-associated myeloid cells (Supplementary Fig. 8a ). Furthermore, in vivo intravital two-photon microscopy showed the presence of FITC-positive cells in tumordraining lymph node (TDLN), as early as 1 h after injection of the labeled construct ( Fig. 3b, Supplementary Fig. 8b and Supplementary  Fig. 9 ), but not in the contralateral lymph nodes ( Supplementary  Fig. 9 ). Additionally, high-resolution imaging by intravital twophoton microscopy revealed an increased number of FITC-positive cells in TDLNs, as well as an accumulation of FITC-labeled CpG-Stat3 siRNAs in perinuclear endocytic vesicles (Fig. 3b, bottom right) , which was also observed in cultured DCs (Fig. 2c) .
We next evaluated the gene silencing and antitumor effects of CpG-Stat3 siRNAs in vivo. Peritumoral injections of the CpG-Stat3 siRNA resulted in effective gene silencing in DCs, macrophages and B cells in TDLNs, compared to control CpG-Luc siRNA, as measured by quantitative real-time PCR (Fig. 3c) . Stat3 inhibition in CD11c + DCs isolated from TDLNs was confirmed at protein level (Fig. 3d) . Furthermore, quantitative real-time PCR and western blot analysis indicated Stat3 silencing in the total TDLNs (Supplementary Fig. 10 ). We also used CpG-Luc siRNA conjugate to confirm that CpG-siRNA conjugates are able to reduce protein expression specifically within myeloid cells in vivo. Mice overexpressing firefly luciferase under control of the β-actin promoter 39 were challenged with tumor cells, followed by repeated peritumoral injections of CpG-Luc siRNA. Results from these experiments indicated effective inhibition of luciferase activity in CD11b + myeloid cells but not in CD4 + lymphocytes within TDLNs (Fig. 3e) .
Both DCs and macrophages in the tumor microenvironment are known to promote immune tolerance 11, 17 . Our previous work demonstrated that Stat3 is persistently activated in myeloid cells in the tumor milieu and that genetic ablation of Stat3 in the myeloid compartment elicits potent antitumor immunity 10 . Furthermore, both CpG and lipopolysaccharide treatment activates Stat3 (refs. 25, 38, 40) , which acts as a negative feedback mechanism to constrain Th1 immune responses. Therefore, we assessed whether the CpG-Stat3 siRNA conjugates could reverse the immunosuppressive effects imposed by the tumor microenvironment and at the same time allow effective antitumor immunity induced by TLR9 triggering. Local treatment with CpG-Stat3 siRNA oligonucleotides inhibited growth of subcutaneously growing B16 melanoma (3-5 mm in diameter at the initial treatment). In contrast, treatment with unconjugated CpG oligonucleotide plus Stat3 siRNA, or CpG-scrambled RNA construct, or GpC-Stat3 siRNA had only minor antitumor effects (Fig. 4a) . The antitumor effects of CpG-Stat3 siRNA were confirmed by using two alternative Stat3 siRNA sequences (data not shown). To directly show that the antitumor effects induced by CpG-Stat3 siRNA were mainly mediated by immune cells, we performed in vivo experiments with antibody-mediated depletion of CD8 + /CD4 + T cells and natural killer (NK) cells. Without CD8 + and CD4 + immune cell populations (possibly also the cross-priming A r t i c l e s CD11c + CD8 + DCs), the effects of CpG-Stat3 siRNA treatment were reduced (Fig. 4b) . The therapeutic effects of CpG-Stat3 siRNA were abrogated in the absence of NK cells (Fig. 4b) .
We confirmed that local treatment with CpG-Stat3 siRNA can reduce growth of other tumors independently of their genetic background. CpG-Stat3 siRNA oligonucleotides inhibited growth of both a poorly immunogenic variant of K1735 melanoma, C4 (ref. 41) , and CT26 colon carcinomas in C3H and BALB/c mice, respectively ( Fig. 4c,d) . Furthermore, CpG-Stat3 siRNA treatment of the carcinoembryonic antigen (CEA) transgenic C57BL/6 mice bearing MC38 colon carcinomas expressing CEA led to tumor regression in three out of four mice (Fig. 4e) . To assess in vivo effects of the CpG-Stat3 siRNA on tumor cells, we stained B16 tumor tissues with fluorescent antibody specific to activated caspase-3. B16 tumors treated with CpG-Stat3 siRNA had undergone more extensive apoptosis than the tumors in the other three treatment groups ( Supplementary  Fig. 11 ). We also investigated the possibility that CpG-Stat3 siRNA could be systemically delivered to achieve gene silencing and antitumor effects. Intravenous injection (i.v.) of CpG-Stat3 siRNA (0.78 nmol) reduced Stat3 expression in DCs within TDLNs relative to CpG-scrambled RNA (Fig. 4f) . Systemic delivery of CpG-Stat3 siRNA to inhibit metastasis was tested in an experimental B16 lung metastasis model. Relatively small amounts of the oligonucleotide (<1 mg/kg) were used for the systemic injection, which led to significant reduction in the number of lung metastases (P = 0.0054; Fig. 4g ). Lower antitumor effect was also observed with CpG-scrambled RNA and CpG oligonucleotide alone. Thus, maximal antitumor effects required conjugation of the CpG TLR9 ligand with a functional Stat3 siRNA.
Modulation of the tumor milieu by the CpG-Stat3 siRNA
To further assess the role of immune modulation in the observed antitumor effects mediated by CpG-Stat3 siRNA conjugate treatment, we analyzed changes in Th1 cytokine and/or chemokines and costimulatory molecule expression by DCs in the TDLNs. Lack of Stat3 in DCs has been shown to upregulate expression of Th1 cytokines/chemokines 10, 20, 42, 43 , which can be greatly amplified by CpG treatment 25 . Injection of the CpG-Stat3 siRNA at the tumor site resulted in upregulation of several Th1 cytokines and chemokines, which were known to be upregulated by Stat3 ablation 10,20,42,43 (Fig. 5a) . It has also been documented that . P = 0.0054 by two-way ANOVA test. Representative photos of lung tissues excised from mice inoculated and treated as described above. The in vivo data are representative of two independent experiments.
A r t i c l e s
DCs with low expression levels of costimulatory molecules mediate immune tolerance 44 , which is one of the proposed mechanisms for tumor-immune evasion induced by Stat3 activation in tumorassociated DCs 10 . We therefore analyzed expression of costimulatory molecules by DCs enriched from TDLNs. CpG-Stat3 siRNA treatment reduced the number of the DCs with low expression of costimulatory molecules, including major histocompatibility complex (MHC) class II, CD80 and CD40, which was accompanied by a modest increase in expression of these costimulatory molecules (Supplementary Fig. 12 ). Stat3 ablation in myeloid cells followed by local treatment using CpG oligonucleotide has been shown to induce potent antitumor innate immune responses that involve neutrophils 25 . We therefore assessed whether CpG-Stat3 siRNA conjugate treatment could lead to neutrophil-associated tumor cell apoptosis. Costaining B16 tumor tissue sections with antibodies specific to activated caspase-3 and neutrophils revealed that CpG-Stat3 siRNA treatment induced massive tumor cell apoptosis (activated caspase-3 positive), which was associated with an increase in tumor-infiltrating neutrophils (Fig. 5b) . The increased number of neutrophils in the tumor after CpG-Stat3 siRNA, and to slightly lesser extent after CpG-Luc siRNA, treatment was further confirmed by flow cytometry (Fig. 5c) .
The ratio of effector to regulatory T cells within the tumor microenvironment is considered indicative of the effect of adaptive immune responses on tumor progression and metastasis 45 . We investigated the numbers of tumor-infiltrating T-cell populations in subcutaneously growing B16 tumors treated locally for 2 weeks with CpG-Stat3 siRNA, CpG-scrambled RNA control or PBS only. Although CpG-Stat3 siRNA treatment did not induce significant changes in overall CD4 + T-cell numbers within the tumors, as shown by flow cytometric analysis (Fig. 6a) , the percentage of CD4 + /FoxP3 + Treg cells within all CD4 + T cells dropped from ~60% to 25% after peritumoral injections of CpG-Stat3 siRNA (Fig. 6b) . We observed an increase in the infiltration of total CD8 + T cells in the tumor stroma, although CpG-scrambled RNA control treatment also led to some recruitment of CD8 + T cells (Fig. 6c) . These effects probably result from TLR9-mediated immunostimulation of tumor-infiltrating A r t i c l e s antigen-presenting cells. Fluorescent immunostaining of frozen tumor tissues with anti-CD8 antibody confirmed data generated by the flow cytometric analysis that CpG-Stat3 siRNA treatment caused increased CD8 + T-cell infiltration in tumors (data not shown). Activation of tumor antigen-specific CD8 + T cells is believed to be critical for immune-mediated antitumor effects. We therefore examined the ability of CpG-Stat3 siRNA treatment to generate CD8 + T cells specific for the B16 tumor antigen, TRP2. Enzyme-linked immunosorbent spot (ELISPOT) assays to determine interferon (IFN)γ production by T cells isolated from TDLNs in response to recall stimulation with TRP2 peptide antigen indicated that in vivo CpG-Stat3 siRNA administration indeed induced antigen-specific CD8 + T cells (Fig. 6d) .
DISCUSSION
We have developed a strategy that combines targeted siRNA delivery and activation of immune cells by covalently linking TLR oligonucleotide agonists to siRNAs. These conjugates encompass three activities in a single molecule: immune cell targeting, TLR activation and immune checkpoint silencing. In addition to TLR9, which was targeted in this study, several other intracellular TLRs, such as TLR3, TLR7 and TLR8, also interact with nucleic acids, suggesting a broad applicability of this approach. Different immune cells could be targeted by using various ligands for these TLRs. TLRs are important for stimulating DC maturation, antigen uptake and presentation, leading to cytotoxic T-lymphocyte activation and CD4 + T helper cell differentiation. Therefore, TLR agonist-siRNA approaches can further stimulate desired immune responses for treating diseases such as cancer and infections. Although it has been established that binding to TLR9 is necessary for CpG-mediated immune activation, it remains to be fully explored how CpG oligonucleotides enter cells 36 . Our results indicated that cellular uptake of both CpG oligonucleotide and the CpG-siRNA constructs can occur in the absence of TLR9. However, TLR9, at least in mouse cells, is essential for CpG-siRNA-mediated gene silencing. Although the exact underlying mechanism(s) remains to be determined, it is possible that triggering TLR9 could effect either endosomal release of CpG-siRNA into the cytoplasm, and/or its intracellular processing.
Although TLR9 is expressed in different types of mouse DCs, its expression is more selective in humans. Whereas the highest levels of constitutive TLR9 expression is observed on human plasmacytoid DCs and B cells, it is also expressed at lower levels on human monocytes and macrophages 26 . These immune cells can serve as antigen-presenting cells and induce innate, adaptive or humoral immunity 27, 29, 46 . A critical role of tumor stromal macrophages and B cells in promoting tumor development has been well documented 47, 48 . Importantly, Stat3 and several other molecules produced by the tumor myeloid population, and possibly tumor-associated B cells, are critical for tumor immunosuppression 17 , and Stat3 activity in the myeloid compartment (and possibly in B cells as well ) promotes Stat3 activity in tumor cells and endothelial cells in the tumor, enhancing tumor cell growth and/or survival 12, [21] [22] [23] . In addition to Stat3, other oncogenic molecules produced by the tumor myeloid/B-cell compartment are also critical in promoting cancer growth and resistance to various therapies. Therefore, being able to target the tumor stromal myeloid cells and/or B cells through CpG-siRNA conjugate molecules is highly desirable for cancer therapies. In addition to normal immune cells, several types of tumor cells, including those of B-cell origin, and some solid tumor cells, are also positive for TLR9 (ref. 49) . Our preliminary results suggested the feasibility of the CpG-siRNA approach to silence genes in TLR9 + tumor cells. For example, treating human TLR9 + tumors in nonobese diabetic/severe combined immunodeficient/IL-2Rγ knockout mice with CpG-Stat3 siRNA resulted in tumor cell apoptosis and tumor growth inhibition (M. Kortylewski and H.Y., unpublished data). More experiments remain to be performed to optimize this approach for potential clinical use.
Our results indicated that the gene silencing effects by CpG-siRNA in cultured cells require high concentrations of the conjugates relative to those required in vivo. Work is underway to determine the possible cause(s) of this difference, which might include serum-associated degradation of CpG-siRNAs or reduction of the overall silencing effect in rapidly dividing cell populations. It is possible that repeated treatments in vivo allow accumulative gene silencing effects, and the crosstalk between various cells in the tumor microenvironment could lead to secondary inhibitory effects on Stat3 activity 23 . The half-life of the constructs at present is limited. Although the CpG oligonucleotide in the construct is phosphothioated, which should resist serum degradation, the siRNA in the chimeric construct is unmodified and negatively charged. Chemically modifying the siRNA to prolong serum stability and to neutralize the negative charge of the siRNA to facilitate endosomal release may improve the efficacy of the TLR agonist-siRNA approach. Furthermore, it has been demonstrated recently that adding triphosphate to the 5′ of siRNA can potentiate the antitumor effects of siRNA by stimulating antitumor immune responses, likely through intracellular RNA sensors such as RIG-I or . It is therefore conceivable that the triphosphate can be incorporated into the CpG-siRNA to further amplify antitumor immunity.
Although more studies are necessary to further understand the mechanism(s), and to improve CpG-siRNA gene silencing effects, our results raise the possibility of using oligonucleotide TLR agonists for siRNA delivery into tumor-associated myeloid cells and B cells, and possibly to certain tumor cells, to inhibit expression of tumorpromoting/immunosuppressive molecules while activating TLR(s) for immune activation.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/.
Note: Supplementary information is available on the Nature Biotechnology website.
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